BeOne Medicines reported a significant improvement in its financial performance, with total revenue reaching $5.34 billion for the full year 2025, marking a 40% increase from $3.81 billion in 2024. The growth was primarily driven by strong sales of its oncology products, particularly BRUKINSA, which generated $3.9 billion in global revenue, up 48.6% from the previous year. In Q1 2026, the company achieved a revenue of $1.51 billion, a 35% increase year over year, supported by robust sales of BRUKINSA and TEVIMBRA. Additionally, BeOne Medicines' free cash flow improved significantly, turning positive at $160.5 million in Q1 2026 from a negative $12.3 million a year earlier, reflecting stronger profitability and lower capital expenditures. The company also reported a GAAP net income of $286.9 million for the full year 2025, a turnaround from a loss of $644.8 million in 2024, driven by improved operating leverage and strong product revenue growth.